Corrigenda: Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia (Leukemia (2017) 31 (1532-1539) DOI: 10.1038/leu.2017.72);Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia

Leukemia

Volumn 31, Issue 7, 2017, Pages 1532-1539

  Han, S H ^a   Kim, S H ^b   Kim, H J ^a   Lee, Y ^c   Choi, S Y ^b   Park, G ^d   Kim, D H ^e   Lee, A ^f   Kim, J ^f   Choi, J M ^e   Kim, Y ^f   Myung, K ^c   Kim, H ^a,g   Kim, D W ^b,d  

^a Sungkyunkwan University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Ulsan National Institute of Science and Technology   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Hanyang University   (South Korea)

^f Sookmyung Women's University   (South Korea)

^g Institute for Basic Science   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; CADMIUM 109; CD34 ANTIGEN; CORDON BLEU PROTEIN LIKE 1; CYCLOHEXIMIDE; DASATINIB; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ITGA4 PROTEIN; MICRORNA 107; MICRORNA 15A; MICRORNA 16; MONOCYTE CHEMOTACTIC PROTEIN 1; MYC PROTEIN; NILOTINIB; P21 ACTIVATED KINASE 1; PONATINIB; PROTEIN; RANTES; SMALL INTERFERING RNA; TAK1 BINDING PROTEIN 2; TAK1 BINDING PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; UBIQUITIN; UNCLASSIFIED DRUG; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; BCR-ABL1 FUSION PROTEIN, HUMAN; CORDON-BLEU PROTEIN-LIKE 1, HUMAN; I KAPPA B KINASE; MICRORNA; MIRN424 MICRORNA, HUMAN; MIRN503 MICRORNA, HUMAN; PYRIMIDINE DERIVATIVE; TRANSCRIPTION FACTOR;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLAST CELL CRISIS; BLAST TRANSFORMATION; CANCER GROWTH; CANCER RESISTANCE; CELL POPULATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOID LEUKEMIA CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EMBRYO DEVELOPMENT; ENZYME ACTIVATION; ENZYME MECHANISM; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; STEM CELL; SURVIVAL RATE; ZEBRA FISH; DRUG RESISTANCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BLAST CRISIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; I-KAPPA B KINASE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICRORNAS; NF-KAPPA B; PYRIMIDINES; TRANSCRIPTION FACTORS;

EID: 85015028700     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.107     Document Type: Erratum

References (46)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
2. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 657-662.
3. Kumar C, Purandare AV, Lee FY, Lorenzi MV. Kinase drug discovery approaches in chronic myeloproliferative disorders. Oncogene 2009; 28: 2305-2313.
4. Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010; 24: 1823-1833.
5. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441-453.
6. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
7. Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005; 105: 804-811.
8. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
9. Masiello D, Gorospe G, Yang AS. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2009; 2: 1.
10. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003; 55: 401-423.
11. Radich J. Structure, function, and resistance in chronic myeloid leukemia. Cancer Cell 2014; 26: 305-306.
12. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374-7379.
13. Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L et al. Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 1641-1650.
14. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-698.
15. Mahon F-X, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373.
16. Von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 2003; 17: 829-838.
17. Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010; 466: 765-768.
18. Nagase T, Ishikawa K-i, Suyama M, Kikuno R, Hirosawa M, Miyajima N et al. Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res 1999; 6: 63-70.
19. Gordon GJ, Bueno R, Sugarbaker DJ. Genes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro. BMC Cancer 2011; 11: 169.
20. Mancina RM, Burza MA, Maglio C, Pirazzi C, Sentinelli F, Incani M et al. The COBLL1 C allele is associated with lower serum insulin levels and lower insulin resistance in overweight and obese children. Diabetes Metab Res Rev 2013; 29: 413-416.
21. Chung YJ, Kim TM, Kim DW, Namkoong H, Kim HK, Ha SA et al. Gene expression signatures associated with the resistance to imatinib. Leukemia 2006; 20: 1542-1550.
22. Kim TM, Ha SA, Kim HK, Yoo J, Kim S, Yim SH et al. Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib. Blood Cancer J 2011; 1: e32.
23. Goh H-G, Kim Y-J, Kim D-W, Kim H-J, Kim S-H, Jang S-E et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma 2009; 50: 944-951.
24. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
25. Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim D-W et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330-3338.
26. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310.
27. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-734.
28. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-2224.
29. Oliver KM, Garvey JF, Ng CT, Veale DJ, Fearon U, Cummins EP et al. Hypoxia activates NF-kappaB-dependent gene expression through the canonical signaling pathway. Antioxid Redox Signal 2009; 11: 2057-2064.
30. Baeuerle PA, Baichwal VR. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997; 65: 111-137.
31. Duncan EA, Goetz CA, Stein SJ, Mayo KJ, Skaggs BJ, Ziegelbauer K et al. IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I dasatinibresistant BCR-ABL+ cells. Mol Cancer Ther 2008; 7: 391-397.
32. Duckett CS, Thompson CB. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 1997; 11: 2810-2821.
33. Shi M, Deng W, Bi E, Mao K, Ji Y, Lin G et al. TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol 2008; 9: 369-377.
34. Ahmed N, Zeng M, Sinha I, Polin L, Wei WZ, Rathinam C et al. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat Immunol 2011; 12: 1176-1183.
35. Shibata Y, Oyama M, Kozuka-Hata H, Han X, Tanaka Y, Gohda J et al. p47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO. Nat Commun 2012; 3: 1061.
36. Tao T, Cheng C, Ji Y, Xu G, Zhang J, Zhang L et al. Numbl inhibits glioma cell migration and invasion by suppressing TRAF5-mediated NF-kappaB activation. Mol Biol Cell 2012; 23: 2635-2644.
37. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409.
38. Zhao C, Xiu Y, Ashton J, Xing L, Morita Y, Jordan CT et al. Noncanonical NF-kappaB signaling regulates hematopoietic stem cell self-renewal and microenvironment interactions. Stem Cells 2012; 30: 709-718.
39. Stainier DY, Kontarakis Z, Rossi A. Making sense of anti-sense data. Dev Cell 2015; 32: 7-8.
40. Espín-Palazón R, Stachura DL, Campbell CA, García-Moreno D, Del Cid N, Kim AD et al. Proinflammatory signaling regulates hematopoietic stem cell emergence. Cell 2014; 159: 1070-1085.
41. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794-2799.
42. Cramer K, Nieborowska-Skorska M, Koptyra M, Slupianek A, Penserga ETP, Eaves CJ et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res 2008; 68: 6884-6888.
43. San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L et al. MicroRNA expression profiling in Imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer 2009; 8: 1.
44. Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M. Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell Oncol 2012; 35: 317-334.
45. Forrest AR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N, Takahashi Y et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 2010; 24: 460-466.
46. Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P et al. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. Cancer Lett 2015; 360: 245-256.